Robin LaChapelle - Jan 25, 2024 Form 3 Insider Report for ArriVent Biopharma, Inc. (AVBP)

Role: Chief Operating Officer
Signature: /s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle
Stock symbol: AVBP
Transactions as of: Jan 25, 2024
Transactions value $: $0
Form type: 3
Date filed: 1/25/2024, 08:38 PM
Next filing: Sep 23, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AVBP	Common Stock						97K	Jan 25, 2024	Direct	F1
holding	AVBP	Common Stock						394K	Jan 25, 2024	Held by The MAKS Yao Trust	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	4.93K	$2.28	Direct	F3, F4
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	7.29K	$2.28	Direct	F4, F5
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	18.2K	$2.28	Direct	F4, F5
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	31.2K	$3.65	Direct	F4, F6
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	59.2K	$6.24	Direct	F4, F7
holding	AVBP	Stock Option (right to buy)							Jan 25, 2024	Common Stock	49.3K	$7.76	Direct	F4, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering.
F2	The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.
F3	The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F4	Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21.
F5	The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F6	The shares underlying this option vest as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F7	The shares underlying this option vest as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F8	The shares underlying this option vest as to 25% on January 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney